The FINANCIAL — Boehringer Ingelheim announced the initiation of a Phase 2 clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel. This potent and selective inhibitor of TRPC6 may alleviate the damage to the lung and decrease the
More
The FINANCIAL — Obesity makes it more difficult to vaccinate adults against influenza. Will this be the case for COVID-19 too? Evidence that obese people have a blunted response to common vaccines was first observed in 1985. Moreover, having obesity, defined as a body
More
The FINANCIAL — Synairgen plc, the respiratory drug discovery and development company which originated from research at the University of Southampton, is pleased to announce positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19
More